Major Program
Phase 0 I II Cancer Prevention Clinical Trials Program
Research Group
Breast and Gynecologic Cancer
Sponsor
National Cancer Institute (NCI)
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT03036930
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to
adults prior to kidney transplantation can help the body build and maintain an effective
immune response during the post-transplant period when they receive immunosuppressive drugs
to prevent transplant rejection. This study will help inform our scientific understanding
about vaccine-induced immune responses among immunosuppressed individuals.
adults prior to kidney transplantation can help the body build and maintain an effective
immune response during the post-transplant period when they receive immunosuppressive drugs
to prevent transplant rejection. This study will help inform our scientific understanding
about vaccine-induced immune responses among immunosuppressed individuals.
Intervention
Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine, Biospecimen Collection, HPV Self-Collection
Condition
Human Papillomavirus Infection
Investigators
Marc T Goodman